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• In adults aged 18-65 with chronic migraines, does subcutaneous 
galcanezumab as compared to placebo reduce the number of 
monthly migraine headache days reported by the patient? 





• 12 % of the population suffers from migraines 
• Along with cranial pain, patients can have visual disturbances, 
nausea, vomiting, dizziness, photophobia, osmophobia, and 
phonophobia 
• Etiology poorly understood, but thought to involve release of 
substance P, calcitonin gene-related peptide (CGRP) and neurokinin 
A 
• Diagnosis of migraine made clinically via history and physical 
exam 
• Current treatment is characterized as preventative or acute 
• Galcanezumab (a fully humanized monoclonal antibody approved 
in 2018) binds to CGRP and blocks its binding to its receptor 
• Systematic review shows that galcanezumab is an effective 
medication that demonstrated a clinically meaningful and positive 
change   
• Statistical benefit was demonstrated in all studies as compared to 
placebo 
• There was no difference in efficacy between the 120mg and 240mg 
doses 
• The most common adverse effect was found to be injection-site pain  
• Since this is a realtively newly approved drug, further studies need to 
be conducted specifically on long-term adverse effects 

















Study 1  
Stauffer, et al. 
Study 2 
Rosen, et al. 
Study 3  
Detke, et al. 
Objective To demonstrate that 
galcanezumab is 
superior to placebo 
in the prvention of 
episodic migraine 
with or without 
aura. 
To characterize 
adult patients with 
episodic migraine 
who achieved 100% 
response to 
galcanezumab 
treatment from two 
other studies.  
To determin if 
subcutaneous 
injection of 120 mg 
and 140 mg 
galcanezumab is 
more effective in 
preventing total 
number of monthly 
migraine headache 
days (MHDs) in 






Study Type Double Blind RCT Post Hoc Analysis Double Blind RCT 







N=1113 (120mg – 
278, 240mg-277, 
placebo-558) 
Study Treatments Galcanezumab 
(120mg and 240mg) 
Galcanezumab 
(120mg and 240 
mg) 
Galcanezumab 
(120mg and 240 
mg) 
Follow Up Period 6 months 6 months 3 months 
Conclusion Galcanezumab 
120mg and 240mg 
both achieved a 
statistically 
significant overall 
mean reduction in 
the number of 
monthly MHDs 
during treatment 
(4.7 and 4.6 days, 
respectively) when 
compared with 




mg or 240 mg 




reduction of MHD 
from baseline 
compared with 
placebo in the 6 









compared to placebo 
in the overall mean 
reduction in number 
of monthyly MHDs 
from baseline (p 
value <0.001). 
 
Figure 3: Action of Galcanezumab on CGRP  
Table 1: Summary of results 
Figure 2: Prisma Diagram  
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